Adults 18 to 70, any sex, with Herpes Zoster. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Frequencies of Glycoprotein E (gE)-Specific Cluster of Differentiation 4 (CD4) / CD8 T Cells With at Least Two Antigen-specific Cytokines: Interferon Gamma (IFN-γ), Interleukin 2 (IL-2), Tumor Necrosis Factor Alpha (TNF-α), CD 40 Ligand (CD40L).Primary· At Month 30 after the first vaccination.
The analysis focused on those gE-specific CD4 T cells secreting at least two different cytokines among IFN-γ, IL-2, TNF-α, and CD40L as determined by intracellular cytokine staining (ICS). No analysis of the immunogenicity data on CD8 T cell response to gE was performed, since no long-term vaccine effect on gE-specific CD8 T cell response was detected.
Group
Value
95% CI
GSK1437173A 18-30 Years Old Group
NA
± NA
GSK1437173A 50-70 Years Old Group
1184.7
± 925.8
Frequencies of Varicella Zoster Virus (VZV)-Specific CD4 / CD8 T Cells With at Least Two Antigen-specific Cytokines (IFN-γ, IL-2, TNF-α, CD40L).Primary· At Month 30 after the first vaccination
The analysis focused on those VZV-specific CD4 T cells secreting at least two different cytokines among IFN-γ, IL-2, TNF-α, CD40L as determined by intracellular cytokine staining (ICS). No analysis of the immunogenicity data on CD8 T cell response to VZV was performed, since no long-term vaccine effect on VZV-specific CD8 T cell response was detected.
Group
Value
95% CI
GSK1437173A 18-30 Years Old Group
NA
± NA
GSK1437173A 50-70 Years Old Group
707.4
± 533.1
Frequencies of Glycoprotein E (gE)-Specific CD4 / CD8 T Cells With at Least Two Antigen-specific Cytokines (IFN-γ, IL-2, TNF-α, CD40L).Primary· At Month 42 after the first vaccination
The analysis focused on those gE-specific CD4 T cells secreting at least two different cytokines among IFN-γ, IL-2, TNF-α, CD40L as determined by intracellular cytokine staining (ICS). No analysis of the immunogenicity data on CD8 T cell response to gE was performed, since no long-term vaccine effect on gE-specific CD8 T cell response was detected.
Group
Value
95% CI
GSK1437173A 18-30 Years Old Group
NA
± NA
GSK1437173A 50-70 Years Old Group
899.8
± 844.4
Frequencies of Varicella Zoster Virus (VZV)-Specific CD4 / CD8 T Cells With at Least Two Antigen-specific Cytokines (IFN-γ, IL-2, TNF-α, CD40L).Primary· At Month 42 after the first vaccination
The analysis focused on those VZV-specific CD4 T cells secreting at least two different cytokines among IFN-γ, IL-2, TNF-α, CD40L as determined by intracellular cytokine staining (ICS). No analysis of the immunogenicity data on CD8 T cell response to VZV was performed, since no long-term vaccine effect on VZV-specific CD8 T cell response was detected.
Group
Value
95% CI
GSK1437173A 18-30 Years Old Group
NA
± NA
GSK1437173A 50-70 Years Old Group
723.8
± 816.4
Frequencies of gE- and VZV-specific CD4/CD8 T Cells With Antigen-specific IFN-γ and/or IL-2 and/or TNF-α and/or CD40L Secretion/Expression.Secondary· At Months 30 and 42 after the first vaccination
The analysis focused on those gE- and VZV-specific CD4 T cells secreting any cytokines among IFN-γ, IL-2, TNF-α, CD40L as determined by intracellular cytokine staining (ICS). No analysis of the immunogenicity data on CD8 T cell response to gE or VZV was performed, since no long-term vaccine effect on gE- and VZV-specific CD8 T cell response was detected.
gE, IL-2 and IFN-γ/TNF-α/CD40L, Month 30
Group
Value
95% CI
GSK1437173A 18-30 Years Old Group
NA
± NA
GSK1437173A 50-70 Years Old Group
1144.8
± 912.2
gE, IFN-γ and IL-2/TNF-α/CD40L, Month 30
Group
Value
95% CI
GSK1437173A 18-30 Years Old Group
NA
± NA
GSK1437173A 50-70 Years Old Group
574.2
± 402.7
gE, TNF-α and IFN-γ/IL-2/CD40L, Month 30
Group
Value
95% CI
GSK1437173A 18-30 Years Old Group
NA
± NA
GSK1437173A 50-70 Years Old Group
806.4
± 721.1
gE, CD40L and IFN-γ/IL-2/TNF-α, Month 30
Group
Value
95% CI
GSK1437173A 18-30 Years Old Group
NA
± NA
GSK1437173A 50-70 Years Old Group
1173.8
± 918.6
gE, IL-2 and IFN-γ/TNF-α/CD40L, Month 42
Group
Value
95% CI
GSK1437173A 18-30 Years Old Group
NA
± NA
GSK1437173A 50-70 Years Old Group
896.9
± 822.9
gE, IFN-γ and IL-2/TNF-α/CD40L, Month 42
Group
Value
95% CI
GSK1437173A 18-30 Years Old Group
NA
± NA
GSK1437173A 50-70 Years Old Group
531.5
± 533.3
gE, TNF-α and IFN-γ/IL-2/CD40L, Month 42
Group
Value
95% CI
GSK1437173A 18-30 Years Old Group
NA
± NA
GSK1437173A 50-70 Years Old Group
506.5
± 550.8
gE, CD40L and IFN-γ/IL-2/TNF-α, Month 42
Group
Value
95% CI
GSK1437173A 18-30 Years Old Group
NA
± NA
GSK1437173A 50-70 Years Old Group
855.5
± 769.7
Anti-gE Antibody (Ab) ConcentrationsSecondary· At months 30 and 42 after the first vaccination
As determined by the Enzyme-Linked Immunosorbent Assay (ELISA) and expressed as ELISA units per milliliter (EL.U/mL).
At Month 30
Group
Value
95% CI
GSK1437173A 18-30 Years Old Group
4008.9
2048.0 – 7847.1
GSK1437173A 50-70 Years Old Group
3390.1
2684.9 – 4280.6
At Month 42
Group
Value
95% CI
GSK1437173A 18-30 Years Old Group
3662.2
905.6 – 14809.0
GSK1437173A 50-70 Years Old Group
2413.1
1698.8 – 3427.8
Anti-VZV Ab ConcentrationsSecondary· At months 30 and 42 after the first vaccination
As determined by the Enzyme-Linked Immunosorbent Assay (ELISA) and expressed as ELISA units per milliliter (EL.U/mL).
At Month 30
Group
Value
95% CI
GSK1437173A 18-30 Years Old Group
5341.8
2247.8 – 12694.5
GSK1437173A 50-70 Years Old Group
4049.3
3340.0 – 4909.2
At Month 42
Group
Value
95% CI
GSK1437173A 18-30 Years Old Group
3988.2
753.2 – 21115.9
GSK1437173A 50-70 Years Old Group
2683.3
1991.2 – 3615.9
Frequencies of gE-specific Memory B CellsSecondary· At months 30 and 42 after the first vaccination
As determined by Enzyme-Linked ImmunoSpot (ELISPOT) assay.
At Month 30
Group
Value
95% CI
GSK1437173A 18-30 Years Old Group
NA
± NA
GSK1437173A 50-70 Years Old Group
3614.2
± 2389.8
At Month 42
Group
Value
95% CI
GSK1437173A 18-30 Years Old Group
NA
± NA
GSK1437173A 50-70 Years Old Group
2696.1
± 2644.0
Frequencies of VZV-specific Memory B CellsSecondary· At months 30 and 42 after the first vaccination
As determined by Enzyme-Linked ImmunoSpot (ELISPOT) assay.
At Month 30
Group
Value
95% CI
GSK1437173A 18-30 Years Old Group
NA
± NA
GSK1437173A 50-70 Years Old Group
4853.8
± 3362.1
At Month 42
Group
Value
95% CI
GSK1437173A 18-30 Years Old Group
NA
± NA
GSK1437173A 50-70 Years Old Group
3488.1
± 2689.1
Number of Subjects With Any Serious Adverse Events (SAEs)Secondary· From Month 30 to study end Month 42 after the first vaccination
SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of existing hospitalization, result in disability/incapacity or was a congenital anomaly/birth defect in the offspring of a study subject.
Group
Value
95% CI
GSK1437173A 18-30 Years Old Group
0
GSK1437173A 50-70 Years Old Group
0
Number of Subjects With Clinically Diagnosed Herpes Zoster (HZ) EpisodesSecondary· From last primary study visit (Month 12) to study end at Month 42 after the first vaccination.
This assay tabulated the number of subjects with clinically diagnosed HZ episodes, defined as any cutaneous HZ-like rash.
Group
Value
95% CI
GSK1437173A 18-30 Years Old Group
0
GSK1437173A 50-70 Years Old Group
0
Sponsor's own description
The safety and immunogenicity of the GSK324332A vaccine has been evaluated up to Month 12 post-vaccination in the primary study. In the extension studies presented here, the persistence of the cellular and humoral immune responses will be evaluated 30 and 42 months after the first vaccination in young and elderly adults who received the GSK324332A vaccine. This protocol posting deals only with objectives \& outcome measures of the extension phase at Months 30 and 42. No new recruitment will be done in these extension phases of the primary study. No vaccines are administered in this phase of the study.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07400003 — Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine
· Phase 1, PHASE2
· recruiting
NCT07307170 — The Analgesic Efficacy and Safety of Mirogabalin in Patients With Herpes Zoster
· NA
· recruiting
NCT07293065 — A Phase III Clinical Trial to Evaluate Long-Term Protective Efficacy of Recombinant Zoster Vaccine (CHO Cell)
· Phase 3
· active not recruiting
NCT07361796 — The Analgesic Efficacy and Safety of Venlafaxine for Prevention of Postherpetic Neuralgia in Patients With Acute Herpes
· NA
· recruiting
NCT07378046 — The Analgesic Efficacy and Safety of Baclofen in Patients With Herpes Zoster
· NA
· recruiting
Other GlaxoSmithKline trials
Trials by the same sponsor.
NCT07569081 — A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflam
· Phase 2, PHASE3
· not yet recruiting
NCT07406347 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose
· Phase 1
· not yet recruiting
NCT07286266 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEH
· Phase 3
· not yet recruiting
NCT07286331 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-E
· Phase 3
· not yet recruiting
NCT07406334 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months
· Phase 1
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by GlaxoSmithKline
Last refreshed: 26 June 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00492648.